Literature DB >> 29286567

Crizotinib in ALK+ inflammatory myofibroblastic tumors-Current experience and future perspectives.

Till-Martin Theilen1, Jan Soerensen2, Konrad Bochennek3, Martina Becker3, Dirk Schwabe3, Udo Rolle1, Thomas Klingebiel2,3, Thomas Lehrnbecher3.   

Abstract

Inflammatory myofibroblastic tumor (IMT) and its subtype epithelioid inflammatory myofibroblastic sarcoma (EIMS) are rare soft-tissue tumors. As about 50% of IMT and 100% of EIMS contain activating rearrangements of the anaplastic lymphoma kinase (ALK) gene, targeted kinase inhibition of ALK by compounds such as crizotinib is a potential treatment option. We performed a literature review and analyzed a total of 30 patients with IMT/EIMS treated with crizotinib. A total of 12 patients achieved complete or partial remission. As preliminary data are promising, a prospective study evaluating crizotinib treatment in patients with unresectable/multifocal ALK+ IMT/EIMS is warranted.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  anaplastic lymphoma kinase (ALK); child; crizotinib; epitheloid inflammatory myofibroblastic sarcoma (EIMS); inflammatory myofibroblastic tumor (IMT)

Mesh：

Substances：

Year:  2017        PMID： 29286567     DOI： 10.1002/pbc.26920

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  14 in total

Review 1.  New advances in the molecular classification of pediatric mesenchymal tumors.

Authors:  Albert J H Suurmeijer; Yu-Chien Kao; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2018-10-11       Impact factor: 5.006

2.  Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor.

Authors:  Paolo Bonvini; Elisabetta Rossi; Angelica Zin; Mariangela Manicone; Riccardo Vidotto; Antonella Facchinetti; Lucia Tombolan; Maria Carmen Affinita; Luisa Santoro; Rita Zamarchi; Gianni Bisogno
Journal:  Front Pediatr       Date:  2021-04-29       Impact factor: 3.418

Review 3.  ALK-negative lung inflammatory myofibroblastic tumor in a young adult: A case report and literature review of molecular alterations.

Authors:  Silvia Angela Debonis; Alberto Bongiovanni; Federica Pieri; Valentina Fausti; Alessandro De Vita; Nada Riva; Lorena Gurrieri; Silvia Vanni; Danila Diano; Laura Mercatali; Toni Ibrahim
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

4.  Identification Of Actionable Genetic Targets In Primary Cardiac Sarcomas.

Authors:  Carmen Salvador-Coloma; María Saigí; Roberto Díaz-Beveridge; Rosa María Penín; María Pané-Foix; Empar Mayordomo; Marcos Melián; Mona Schuler; Xavier García Del Muro; Jaime Font de Mora
Journal:  Onco Targets Ther       Date:  2019-11-07       Impact factor: 4.147

Review 5.  Translating Molecular Profiling of Soft Tissue Sarcomas into Daily Clinical Practice.

Authors:  Celine Jacobs; Lore Lapeire
Journal:  Diagnostics (Basel)       Date:  2021-03-14

Review 6.  Molecular targeted therapy for advanced or metastatic soft tissue sarcoma.

Authors:  Jin Yuan; Xiaoyang Li; Shengji Yu
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

7.  Clinicopathological features of gastric inflammatory myofibroblastic tumor: Report of five cases.

Authors:  Yangkun Wang; Lan Shen; Tian Yun; Chaoya Zhu; Ping Wang; Sunan Wang
Journal:  Exp Ther Med       Date:  2021-07-01       Impact factor: 2.447

8.  Inflammatory Myofibroblastic Tumors in Children: A Clinical Retrospective Study on 19 Cases.

Authors:  Min Da; Bo Qian; Xuming Mo; Cheng Xu; Haiyan Wu; Bin Jiang; Wei Peng; Jirong Qi; Jian Sun; Kaihong Wu
Journal:  Front Pediatr       Date:  2021-07-08       Impact factor: 3.418

9.  Rare, rarer, rarest: lessons from the largest retrospective study to date on mediastinal sarcomas.

Authors:  Michael A den Bakker; Philipp Ströbel
Journal:  Mediastinum       Date:  2019-09-20

10.  Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report.

Authors:  Danila Comandini; Fabio Catalano; Massimiliano Grassi; Guido Pesola; Rossella Bertulli; Antonio Guadagno; Bruno Spina; Matteo Mascherini; Franco De Cian; Federico Pistoia; Sara Elena Rebuzzi
Journal:  Front Oncol       Date:  2021-06-15       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.